# ai3Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ai3bio

- Industry: Biotechnology
- Headquarters: US
- Website: www.ai3.bio
- Total disclosed funding: $48M
- Latest round: Series A (Sep 29, 2026)
- Investors on record: 4

## About

based in Massachusetts, US, and co-founded in 2025, ai3Bio is a biotechnology company that research and develops immunology-based therapies for autoimmune diseases through its platforms use lipid nanoparticle (LNP)/mRNA and antibody technologies to identify and eliminate disease-causing T cells directly in vivo, aiming to restore immune balance at the source of disease.

## Funding rounds

- Series A, Sep 29, 2026, $48M — Cockrell Interests, Ziff Capital Partners, Tanis Venture Management, UPMC Enterprises

## Investors

- Cockrell Interests (https://capitalatlas.ai/funds/cockrell-interests) — Series A
- Ziff Capital Partners — Series A
- Tanis Venture Management (https://capitalatlas.ai/funds/tanis-venture-management) — Series A
- UPMC Enterprises (https://capitalatlas.ai/funds/upmc-enterprises) — Series A